Navigation Links
Bionovo, Inc. to Announce Fourth Quarter and Year-End Financial Results on Thursday, March 12, 2009
Date:3/6/2009

Company to Review Plans for 2009

EMERYVILLE, Calif., March 6 /PRNewswire-FirstCall/ -- Bionovo, Inc. (Nasdaq: BNVI) announced today that it will release financial results for the fourth quarter and the year ended December 31, 2008 on Thursday, March 12, 2009. The Company will conduct a conference call and web cast to review the financial results and the Company's plans for 2009 on Thursday, March 12, 2009 at 4:30 p.m. ET.

Interested parties can access the call by dialing (877) 356-5706 or (706) 643-0580, or can listen via a live Internet web cast, which can be found at http://bionovo.com/investors/events. A replay of the call is available via web cast at http://bionovo.com/investors/events for 30 days or by playback at (800) 642-1687 or (706) 645-9291, access code 88102099, through March 15, 2009.

About Bionovo, Inc.

Bionovo, Inc. is a pharmaceutical company focused on the discovery and development of safe and effective treatments for women's health and cancer, markets with significant unmet needs and billions in potential annual revenue. The company applies its expertise in the biology of menopause and cancer to design new drugs derived from botanical sources which have novel mechanisms of action. Based on the results of early and mid-stage clinical trials, Bionovo believes they have discovered new classes of drug candidates within their rich pipeline with the potential to be leaders in their markets. Bionovo is headquartered in Emeryville, California and is traded on the NASDAQ Capital Market under the symbol, "BNVI". For more information about Bionovo and its programs, visit: http://www.bionovo.com. BNVI-F


'/>"/>
SOURCE Bionovo, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Versus Technology Announces First Quarter Results
2. Orchid Cellmark to Announce Fourth Quarter and Year-End 2008 Financial Results on March 16, 2009
3. Valeant Pharmaceuticals Announces Annual Stockholder Meeting Date
4. Gaiam to Announce Fourth Quarter 2008 and Year End Results
5. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Revised Timing for Commercial Availability of Savella(TM)
6. Stereotaxis Announces First Uses of the NAVISTAR(R) RMT THERMOCOOL(R) Catheter
7. Therapure Biopharma Inc. and LFB Biotechnologies Announce Development Services Contract for New Therapeutic Protein
8. Polymer Group, Inc. Announces Fourth Quarter and Year-End 2008 Earnings Conference Call
9. China Healthcare Acquisition Corp. Announces Stockholder Approval of Charter Amendment to Permit Early Distribution of Its Trust Fund and to Permit Its Continued Existence Without Blank Check Company Provisions and Sets Payment Date
10. Trubion Announces Dates for Fourth-Quarter and Year-Ended 2008 Earnings Conference Call
11. Karmanos Cancer Institute Announces Interim Leadership
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... of Canadians surveyed said they would participate in public ... of genetic conditions, only 80 per cent said they ... sequence their newborns, genomes.,Most newborns in North America have ... two of life in which a tiny amount of ... about five to 54 conditions, depending on the state ...
(Date:4/17/2014)... Johnston, whose work has transformed cancer care in Northern ... European Academy of Cancer Sciences., The Academy, which was ... highly distinguished oncologists and cancer researchers which aims to ... Europe. , Professor Johnston, whose leadership has seen cancer ... of the UK league table to near the top, ...
(Date:4/17/2014)... more research to be carried out into HIV ... In a paper in The Lancet Infectious ... colleagues in the department of Parasitology and researchers ... University of Cambridge and the Royal Veterinary College ... of HIV/AIDS and schistosomiasis of children, and found ...
(Date:4/16/2014)... PHOENIX, Ariz. April 15, 2014 The Translational ... philanthropists at their annual Founders Dinner for their support ... The event took place March 28 in Scottsdale. , ... Catherine Ivy Foundation, received TGen,s John S. McCain Leadership ...
(Date:4/16/2014)... A team that includes scientists from the School of Medicine ... Antonio, Johns Hopkins University and St. Mary,s University reported the ... infect the body. , The fungal pathogen Candida albicans ... is the most common fungal pathogen to infect humans. It ...
Breaking Medicine News(10 mins):Health News:Researcher looks at public perceptions around newborn testing 2Health News:Researcher looks at public perceptions around newborn testing 3Health News:More research called for into HIV and schistosomiasis coinfection in African children 2Health News:TGen honors Catherine Ivy and Craig Jackson with Leadership; Collaborative Spirit awards 2
... illness as college grads, study finds , , WEDNESDAY, May 6 ... the worst health, a new study finds. , Almost ... in less than very good health, and levels of health ... released Wednesday by the Robert Wood Johnson Foundation Commission to ...
... Lower Risk of Fractures WASHINGTON, May 6 Of ... families, one of the most important is health knowledge, ... the National Osteoporosis Foundation. A Gift from Mothers ... Osteoporosis Awareness and Prevention Month, which is attempting to ...
... May 6 Endo Pharmaceuticals (Nasdaq: ENDP ) ... America and Merrill Lynch 2009 Health Care Conference on Wednesday, ... Holveck, President and Chief Executive Officer of Endo, will review ... live and can be accessed from Endo,s website at ...
... May 6 /PRNewswire-Asia/ -- China Medicine Corporation,(OTC ... Company"), a developer,and a leading distributor of ... medicines (TCM), nutritional and dietary supplements, and,medical ... it will conduct,a conference call at 9:00 ...
... Net service revenues increased 77% to $69.2 million- Visiting ... million- Net income increased 118% to $5.6 million- Diluted ... more shares outstandingLOUISVILLE, Ky., May 6 Almost Family, ... provider of home health nursing services, announced today its ...
... catch high percentage of skin cancers at Women,s Dermatologic ... As champions of sun safety and skin health, ... (WDS) provided free skin cancer screenings and education ... SC recently. In a busy day of outreach, local ...
Cached Medicine News:Health News:Less Education May Mean Poorer Health 2Health News:Less Education May Mean Poorer Health 3Health News:Mothers Play a Powerful Role in Determining Strength of Daughters' Bones 2Health News:Mothers Play a Powerful Role in Determining Strength of Daughters' Bones 3Health News:Mothers Play a Powerful Role in Determining Strength of Daughters' Bones 4Health News:Endo to Present at Bank of America and Merrill Lynch 2009 Health Care Conference 2Health News:Endo to Present at Bank of America and Merrill Lynch 2009 Health Care Conference 3Health News:Endo to Present at Bank of America and Merrill Lynch 2009 Health Care Conference 4Health News:China Medicine Announces Conference Call to Discuss First Quarter 2009 Results 2Health News:Almost Family Reports First Quarter 2009 Results 2Health News:Almost Family Reports First Quarter 2009 Results 3Health News:Almost Family Reports First Quarter 2009 Results 4Health News:Almost Family Reports First Quarter 2009 Results 5Health News:Almost Family Reports First Quarter 2009 Results 6Health News:Almost Family Reports First Quarter 2009 Results 7Health News:Almost Family Reports First Quarter 2009 Results 8Health News:Almost Family Reports First Quarter 2009 Results 9Health News:Almost Family Reports First Quarter 2009 Results 10Health News:Almost Family Reports First Quarter 2009 Results 11Health News:Almost Family Reports First Quarter 2009 Results 12Health News:Almost Family Reports First Quarter 2009 Results 13Health News:Almost Family Reports First Quarter 2009 Results 14Health News:South Carolina Dermatologists Win Tennis Fans' Attention With Free Skin Cancer Checks and Sun Safety Tips 2Health News:South Carolina Dermatologists Win Tennis Fans' Attention With Free Skin Cancer Checks and Sun Safety Tips 3
(Date:1/15/2014)... Texas , Jan. 15, 2014  Novation, the leading ... awarded several new IT value-added reseller (VAR) national contracts ... IT goods and services at lower costs. These include ... services such as initiative assistance and ongoing IT consulting ...
(Date:1/15/2014)... 15, 2014 BreedIT Corp (OTC: BRDT), ... distributor of highly sophisticated agro-breeding solutions for plant breeders ... the Company,s board of directors appointed chemistry and pharmaceutical ... new member of the board. From 1975 ...
(Date:1/15/2014)... PHILADELPHIA , Jan. 15, 2014  Echo Therapeutics, Inc. ... company developing its Symphony® CGM System as a non-invasive, ... Robert F. Doman , Executive Chairman and Interim CEO ... Capital Markets, Tenth Annual Equity Conference. ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... EAST HANOVER, N.J., June 1, 2011 Novartis Pharmaceuticals ... its current oncology products and investigational agents at the ... Oncology (ASCO). These data underscore the company,s commitment to ... cancer. "Through our commitment to R&D and ...
... Actavis, an international generic pharmaceutical company, today announced that ... Administration to market Donepezil Hydrochloride Tablets a generic equivalent of ... Tablets 5mg and 10mg had US total sales of approximately ... according to IMS Health.     About ...
Cached Medicine Technology:Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 2Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 3Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 4Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 5Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 6Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 7Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 8Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 9Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 10Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 11Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 12Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 13Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 14Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 15Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 16Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 17Novartis highlights extensive data on numerous compounds at ASCO in multiple cancers, including Phase III studies in GIST and myelofibrosis 18Actavis Receives FDA Approval of Donepezil Hydrochloride Tablets in the U.S. 2
Finesse electrosurgical generator (100-120 VAC) utilizes a patented design that integrates the electrosurgical generator and smoke evacuation system into a single compact unit....
NS2000 Bipolar Generator provides precise coagulation without tissue sticking....
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
The ExcaliburPlus PC is the most powerful isolated ESU with 10,000 V PTP in spray coag....
Medicine Products: